Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

NCT03409848 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Esophageal Cancer
Adenocarcinoma Gastric
HER2 Positive Gastric Cancer
Metastatic Gastric Cancer
GastroEsophageal Cancer

Interventions

DRUG: Nivolumab
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]